GYRE THERAPEUTICS’ HYDRONIDONE MET THE PRIMARY ENDPOINT AND DEMONSTRATED STATISTICALLY SIGNIFICANT FIBROSIS REGRESSION IN PIVOTAL PHASE 3 TRIAL FOR THE TREATMENT OF CHB-ASSOCIATED LIVER FIBROSIS IN CHINA

Reuters · 05/22 20:01

Please log in to view news